Armata Pharmaceuticals initiated with a Buy at JonesResearch

JonesResearch analyst Debanjana Chatterjee initiated coverage of Armata Pharmaceuticals (ARMP) with a Buy rating and $15 price target What differentiates Armata from other companies developing clinical-stage phage therapies is the combination of a proprietary off-the-shelf phage platform and in-house cGMP manufacturing that can consistently produce high-purity, high-titer, clinical-grade phage cocktails, the analyst tells investors. Armata is developing AP-SA02 and AP-PA02 against difficult-to-treat Staph. aureus bacteremia and Pseudomonas aeruginosa infections, respectively, the analyst noted.